Gerresheimer gets off to good start in new financial year

Dusseldorf (ots) -

- Cross-reference: Press release including Group Key Figures is
available at http://www.presseportal.de/dokumente -

- Group revenues in the first quarter of 2011 rise by 5.2 percent
to EUR 236.6m
- Adjusted EBITDA margin reaches 17.7 percent compared with 17.0
percent in the prior-year period
- Tripling of net income to EUR 7.1m and earnings per share to
EUR 0.20
- Acquisition in Brazil accelerates successful expansion in the
emerging countries

Gerresheimer AG, one of the leading global suppliers to the pharma
and healthcare industry, got off to a good start in the new financial
year. "We continued on our successful course in the new financial
year. We expect particularly strong growth over the coming years in
the emerging countries. Our latest acquisition of the Brazilian
company Vedat strengthens our position in the emerging markets and
expands our product portfolio," says Uwe Röhrhoff, CEO of
Gerresheimer AG.

In the first quarter of the financial year 2011 (December 1, 2010
to February 28, 2011) Gerresheimer substantially increased its
revenues, with a 5.2 percent rise to EUR 236.6m. At constant exchange
rates the growth rate was 2.9 percent. The main growth drivers were
products like pharma bottles, injection vials, ampoules, insulin pens
and inhalers. There was also a further rise in demand for cosmetics
products.

In the first quarter of 2011 Gerresheimer increased its adjusted
EBITDA to EUR 41.8m, 9 percent up on the prior year. The adjusted
EBITDA margin improved by 0.7 percentage points on the prior year to
17.7 percent. Net income almost tripled to EUR 7.1m in the first
quarter. Earnings per share also improved substantially from EUR 0.06
to EUR 0.20. Net financial debt was reduced by EUR 84.4m in
comparison with the prior year to EUR 318.2m. In addition,
Gerresheimer introduced early refinancing.

"The worldwide demand for medicines will continue to rise in the
coming years. Demographic change, increasing incidence of acute and
chronic diseases, growth of self-medication and the need for
healthcare in the emerging countries will contribute to this. These
megatrends provide the basis for our future growth. With our products
and services we can contribute to improving health and well- being,"
says Röhrhoff.

Outlook

For the financial year 2011 Gerresheimer's guidance is that
revenue growth as reported including Vedat will be 7 to 8 percent
This is equivalent to revenue growth of 6 to 7 percent at constant
exchange rates. The company assumes unchanged that the adjusted
EBITDA margin will reach around 20%. In 2011 the company expects to
invest around EUR 80m.

contact:
Gerresheimer AG
Benrather Strasse 18 - 20
40213 Düsseldorf
Germany

Jens Kürten
Director Corporate Communication & Marketing
Telephone +49 211 6181-250
Fax +49 211 6181-241
E-mail j.kuerten@gerresheimer.com
Internet www.gerresheimer.com